Tamoxifen-Induced Hepatotoxicity in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer

Management and Monitoring

The National Comprehensive Cancer Network recommends switching to an aromatase inhibitor (anastrozole, letrozole, or exemestane) for postmenopausal women requiring discontinuation of tamoxifen due to hepatotoxicity, as these agents do not cause clinically significant hepatic steatosis, with a strength of evidence based on trials such as ATAC, BIG 1-98, and IES showing superior disease-free survival with aromatase inhibitors compared to tamoxifen 1, 2
Aromatase inhibitors are recommended as first-line or sequential therapy in postmenopausal women and lack the hepatic steatosis risk profile of tamoxifen, with studies demonstrating their efficacy and safety 1, 2, 4

For patients with pre-existing liver disease, the American College of Clinical Pharmacology suggests considering aromatase inhibitors as first-line therapy, with dose adjustment based on serum tamoxifen levels and more frequent monitoring if tamoxifen is used 3